FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paco Welsing

Research Profile

Disorders

Rheumatoid Arthritis

Chemicals & Drugs

Concepts & Ideas

Procedures

Activities & Behaviors

Cost Benefit Analysis

Co-author Network

Publications

TOP 3
P A J M Vos; Paco M J Welsing; Simon C Mastbergen; J C M Oostveen; M Reijman; J Damen; Jeroen DeGroot; André Huisman; Floris P J G Lafeber
Skin pentosidine in very early hip/knee osteoarthritis (CHECK) is not a strong independent predictor of radiographic progression over 5 years follow-up.
M C van der Goes; M J van der Veen; J H van der Werf; Paco M J Welsing; M F Bakker; J W G Jacobs; M S Jurgens; J W J Bijlsma
Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
Margot B Kinds; Floris P J G Lafeber; Anne C A Marijnissen; Johannes W J Bijlsma; Maarten Boers; Paco M J Welsing
Quantitative radiographic features of early knee osteoarthritis: development over 5 years and relationship with symptoms in the CHECK cohort.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paco Welsing (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: P A J M Vos; Paco M J Welsing; Simon C Mastbergen; J C M Oostveen; M Reijman; J Damen; Jeroen DeGroot; André Huisman; Floris P J G Lafeber
Skin pentosidine in very early hip/knee osteoarthritis (CHECK) is not a strong independent predictor of radiographic progression over 5 years follow-up.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2013;21(6):823-30.
2013: M C van der Goes; M J van der Veen; J H van der Werf; Paco M J Welsing; M F Bakker; J W G Jacobs; M S Jurgens; J W J Bijlsma
Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013;24(4):1429-36.
2013: Margot B Kinds; Floris P J G Lafeber; Anne C A Marijnissen; Johannes W J Bijlsma; Maarten Boers; Paco M J Welsing
Quantitative radiographic features of early knee osteoarthritis: development over 5 years and relationship with symptoms in the CHECK cohort.
The Journal of rheumatology 2013;40(1):58-65.
2013: Janet Wesseling; Sita M A Bierma-Zeinstra; Joost Dekker; Kees J Gorter; Margreet Kloppenburg; Leo Roorda; Paco M J Welsing; Johannes W J Bijlsma
Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study.
Rheumatology (Oxford, England) 2013;52(1):180-8.
2013: Maud S Jurgens; Floris P J G Lafeber; Iet A van Albada-Kuipers; Paco M J Welsing; Marije F Bakker; Johannes W J Bijlsma; Ercolie R Bossema; Johan C Ehrlich; Rinie Geenen; Johannes W G Jacobs
Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?
Arthritis care & research 2013;65(1):88-93.
2012: Corinne Klop; Arief Lalmohamed; Hubert G M Leufkens; Simon C Mastbergen; Willemijn H Noort-van der Laan; Johannes W J Bijlsma; Frank de Vries; Paco M J Welsing
COX-2-selective NSAIDs and risk of hip or knee replacements: a population-based case-control study.
Calcified tissue international 2012;91(6):387-94.
2012: Marije F Bakker; Johannes W J Bijlsma; Guy Cavet; Michael Centola; Douglas J Haney; Lyndal K Hesterberg; Johannes Wg Jacobs; Floris P J G Lafeber; Yijing Shen; Dustin R Smith; Joel A G van Roon; Paco M J Welsing
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study.
Annals of the rheumatic diseases 2012;71(10):1692-7.
2012: Maud S Jurgens; Paco M J Welsing; Johannes W G Jacobs
Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.
Clinical and experimental rheumatology 2012;30(4 Suppl 73):S56-63.
2012: Marije F Bakker; Johannes W J Bijlsma; Johannes W G Jacobs; Aike A Kruize; Floris P J G Lafeber; Christina van Booma-Frankfort; Maaike J van der Veen; Simone A Vreugdenhil; Paco M J Welsing
Misclassification of disease activity when assessing individual patients with early rheumatoid arthritis using disease activity indices that do not include joints of feet.
Annals of the rheumatic diseases 2012;71(6):830-5.
2012: Marije F Bakker; Johannes W J Bijlsma; Monique A W Geurts; Johannes W G Jacobs; Zalima N Jahangier-de Veen; Floris P J G Lafeber; Janneke Tekstra; Evelien Ton; GA van Albada-Kuipers; Maaike J van der Veen; Jacobine H van der Werf; CM Verhoef; S M M Verstappen; Paco M J Welsing
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
Annals of internal medicine 2012;156(5):329-39.
2011: Jos N Hoes; J W G Jacobs; Floris P J G Lafeber; Willem F Lems; M C van der Goes; N J van der Zijl; D H van Raalte; Paco M J Welsing; D den Uyl; M Diamant; J W J Bijlsma
Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids.
Annals of the rheumatic diseases 2011;70(11):1887-94.
2011: M F Bakker; J W J Bijlsma; J W G Jacobs; Floris P J G Lafeber; S P Linn-Rasker; E Ton; Christina van Booma-Frankfort; S A Vreugdenhil; Paco M J Welsing
Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study.
Annals of the rheumatic diseases 2011;70(6):1099-103.
2010: M F Bakker; J W G Jacobs; Paco M J Welsing; J H van der Werf; S P Linn-Rasker; Maaike J van der Veen; Floris P J G Lafeber; J W J Bijlsma
Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.
Annals of the rheumatic diseases 2010;69(10):1849-52.
2010: A Risselada; Janneke Tekstra; Y K Teng; Paco M J Welsing; F Breedveld; J M van Laar; J W J Bijlsma
Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
Annals of the rheumatic diseases 2010;69(10):1891-2.
2010: Frits G W Cleveringa; Paco M J Welsing; Maureen van den Donk; Kees J Gorter; Louis Niessen; G E H M Rutten; W Ken Redekop
Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
Diabetes care 2010;33(2):258-63.
2006: Timothy Radstake; Barbara Franke; Mark Wenink; K C A M Nabbe; Marieke Coenen; Paco M J Welsing; Ezio Bonvini; Scott Koenig; Wim B van den Berg; Pilar Barrera; P L C M van Riel
The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis.
Arthritis and rheumatism 2006;54(12):3828-37.
2006: W Kievit; Paco M J Welsing; Eddy M M Adang; A M Eijsbouts; Paul Krabbe; P L C M van Riel
Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health.
Arthritis and rheumatism 2006;55(5):745-50.
2006: Paco M J Welsing; George F Borm; P L C M van Riel
Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective.
The Journal of rheumatology 2006;33(3):501-7.
2006: Paco M J Welsing; Johan L Severens; Margriet Hartman; Anke M van Gestel; P L C M van Riel; R F J M Laan
The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.
PharmacoEconomics 2006;24(10):1011-20.
2006: George F Borm; Rein M G J Houben; Paco M J Welsing; Gerhard A Zielhuis
An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint.
Journal of clinical epidemiology 2006;59(1):1-6.
2005: Timothy Radstake; Fred C G J Sweep; Paco M J Welsing; Barbara Franke; Sita H H M Vermeulen; Anneke Geurts-Moespot; Thierry Calandra; Rachelle Donn; P L C M van Riel
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.
Arthritis and rheumatism 2005;52(10):3020-9.
2005: Paco M J Welsing; Jaap Fransen; P L C M van Riel
Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
Arthritis and rheumatism 2005;52(9):2616-24.
2005: Marcel Flendrie; M C W Creemers; Paco M J Welsing; P L C M van Riel
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
Rheumatology (Oxford, England) 2005;44(4):472-8.
2004: Paco M J Welsing; Johan L Severens; Margriet Hartman; P L C M van Riel; R F J M Laan
Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Arthritis and rheumatism 2004;51(6):964-73.
2004: Paco M J Welsing; Robert B M Landewé; P L C M van Riel; Maarten Boers; Anke M van Gestel; Sjef van der Linden; Hilde L Swinkels; Désirée van der Heijde
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis.
Arthritis and rheumatism 2004;50(7):2082-93.
2004: Paco M J Welsing; P L C M van Riel
The Nijmegen inception cohort of early rheumatoid arthritis.
The Journal of rheumatology. Supplement 2004;69():14-21.
2004: Timothy Radstake; Barbara Franke; Suzanne Hanssen; Mihai G Netea; Paco M J Welsing; Pilar Barrera; Leo A B Joosten; P L C M van Riel; Wim B van den Berg
The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome.
Arthritis and rheumatism 2004;50(3):999-1001.
2003: Paco M J Welsing; Johan L Severens; R F J M Laan
Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result.
Rheumatology (Oxford, England) 2003;42(12):1574-5; author reply 1573-4.
2003: Marcel Flendrie; M C W Creemers; Paco M J Welsing; Alfons A den Broeder; P L C M van Riel
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
Annals of the rheumatic diseases 2003;62 Suppl 2():ii30-3.
2001: Paco M J Welsing; Anke M van Gestel; Hilde L Swinkels; L A Kiemeney; P L C M van Riel
The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis.
Arthritis and rheumatism 2001;44(9):2009-17.
2001: Michiel M Zandbelt; Paco M J Welsing; Anke M van Gestel; P L C M van Riel
Health Assessment Questionnaire modifications: is standardisation needed?
Annals of the rheumatic diseases 2001;60(9):841-5.